TrialClinical cardiology2017

Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study.

Suguru Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.